GlobeNewswire Inc.··Cytokinetics, IncorporatedCytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending
Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials